for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Checkpoint Therapeutics Inc

CKPT.OQ

Latest Trade

1.89USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.50

 - 

5.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.89
Open
--
Volume
--
3M AVG Volume
1.23
Today's High
--
Today's Low
--
52 Week High
5.17
52 Week Low
1.50
Shares Out (MIL)
38.00
Market Cap (MIL)
71.81
Forward P/E
-2.92
Dividend (Yield %)
--

Latest Developments

More

Checkpoint Therapeutics Says Q2 Loss Per Share $0.15

Checkpoint Therapeutics Q1 Loss Per Share $0.18

Checkpoint Therapeutics Announces Positive Interim Clinical Results Of Anti-Pd-L1 Antibody Cosibelimab

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

Industry

Biotechnology & Drugs

Contact Info

2 Gansevoort St Fl 9

+1.212.5544366

http://www.checkpointtx.com

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019(E)

0.0K
EPS (USD)

2019(E)

-0.645
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.18
Price To Book (MRQ)
9.69
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-214.45
Return on Equity (TTM)
-143.25

Latest News

Latest News

BRIEF-Checkpoint Therapeutics files for mixed shelf offering of up to $100 mln - SEC filing

* Checkpoint Therapeutics Inc - files for mixed shelf offering of up to $100 million - SEC filing Source text: (http://bit.ly/2zKSDGZ) Further company coverage:

BRIEF-Checkpoint Therapeutics receives orphan drug designation for CK-101

* Checkpoint Therapeutics receives orphan drug designation for ck-101 for the treatment of egfr mutation-positive non-small cell lung cancer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up